Neveux LM, Palomaki GE, Larrivee DA:
"Refinements in managing maternal weight adjustment for interpreting prenatal screening results”.
Prenat. Diagn. 1996; 16: 1115-19.

Watt HC, Wald NJ, Smith D:
“Effect of allowing for ethnic group in prenatal screening for Down’s Syndrome”.
Prenat. Diagn. 1996; 16: 691-698.

Wald NJ, Cuckle HS, Densem JW:
“Maternal serum unconjugated oestriol and human chorionic  gonadotropin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down’s Syndrome”.
Br. J. Obstet. Gynecol. 1992; 99: 51-53.

Crossley JA, Berry E, Aitken DA:
“Insulin-dependent diebetes mellitus and prenatal screening results: current experience from a regional screening program”.
Prenat. Diagn. 1996; 16: 1039-42.

Wald NJ, Cuckle HS, Wu T:
“Maternal serum unconjugated estriol and human chorionic  gonadotrophin levels in twin pregnancies: implications for screening for Down’s Syndrome”.
Br. J. Obstet. Gynecol. 1991; 98: 905-908.

Palomaki GE, Knight GJ, Haddow JE:
“Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol and hCG: impact on Down’s syndrome screening”.
Obstet. Gynecol. 1993; 81: 675-678.

Zimmermann R, Reynolds TM, John R:
“Age-indipendent indices in second-trimester serum screening for Down’s Syndrome are useless”.
Prenat. Diagn. 1996; 16: 79-82.

Dar A, Merksamer R, Berdichevsky:
“Maternal serum markers levels in consecutive pregnancies: a possible genetic predisposition to abnormal levels”.
Am. J. Med. Genet. 1996; 61: 154-157.

Chard T, Macintosh MCM:
“Screening for Down’s Syndrome”.
J. Perinat. Med. 1995; 23: 421-436.

Hook EB:
“Rates of chromosome abnormalities at different maternal ages”.
Obstet. Gynecol. 1981; 58: 282-285.

Phillips OP, Elias S, Shulman LP:
“Maternal serum screening for fetal Down Syndrome in women less than 35 years of age using alpha-fetoprotein, hCG and unconjugated estriol: a prospective-2 years study”.
Obstet. Gynecol. 1992; 80: 353-358.

Burton BK, Prins GS, Verp MS:
“A prospective trial of prenatal screening for Down Syndrome by means of maternal serum alpha-fetoprotein, hCG and unconjugated estriol”.
Am. J. Obstet. Gynecol. 1993; 169: 526-530.

MacDonald ML, Wagner RM, Slotnick RN:
“Sensitivity and specificity of screening for Down Syndrome wiyh alpha-fetoprotein, hCG, unconjugated estriol and maternal age”.
Obstet. Gynecol. 1991; 77: 63-68.

Haddow JE, Palomaki GE, Knight GJ:
“Prenatal screening for Down’s Syndrome with use of maternal serum markers”.
N. Engl. J. Med. 1992; 327: 588-593.

Haddow JE, Palomaki GE, Knight GJ:
“Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening”.
N. Engl. J. Med. 1994; 330: 1114-8.

Ettore G, Marra G, Puglisi F:
“Lo screening biochimico prenatale per la sindrome di Down e i difetti del tubo neurale nel II trimestre di gravidanza”.
Giorn. It. Ost. Gin. 1996; 11: 629-635.

Wald NJ, Cuckle HS; Densem JW:
“Maternal serum screening for Down’s Syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight”.
Br. J. Obstet. Gynecol. 1992; 99: 144-149.

Maciewicz A, Berborowicz I:
“The in-vitro production of alpha-fetoprotein variants by human fetal organs”.
Oncodev. Biol. Med. 1980; 1: 251-255.

Ross GT:
“Clinical relevance of research on the structure of human chorionic gonadotrophin”.
Am. J. Obstet. Gyn. 1977; 129: 795-811.

Canick JA, Knight GJ; Palomaki GE, Haddow JE, Crickle HS, Wald NJ:
“Low second trimester maternal serum unconjugated estriol in pregnancies with Down’s Syndrome”.
Br. J. Obstet. Gynecol. 1988; 95: 330-333.

Iaccarino M, Arduini D, Ventruto V:
“Diagnostica ecografica ostetrico ginecologica ragionata”.
Verduci Ed. 1996.

Canini S, Volpe G, De Biasio P, Famularo L:
“Gli screening biochimici prenatali”.
Giorn. It. Ost. Gin. 1996; 11: 619-625.